drugset
drugset / Trial / NCT03590366

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

NCT03590366 ↗

Phase 2 Completed 140 enrolled AOBiome LLC bioRASI, LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.

Timeline

Start
2018-07-02
Primary completion
2019-02-11
Completion
2019-03-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator B244 Other / unclassified — Topical

Indications

rosacea